Mitochondrial Transfer Therapies Move Closer to Clinical Reality

Cardiovascular disease is increasingly understood as a disorder of cellular energetics, not merely hemodynamic dysfunction. Current guideline-directed therapies reduce myocardial workload but do not restore the bioenergetic capacity of diseased cardiomyocytes, leaving a persistent therapeutic gap. This 2026 review from Stanford's Cardiovascular Institute, published in Circulation Research, synthesizes the rapidly expanding field of intercellular mitochondrial transfer and its translational potential.

The authors describe three primary conduits for mitochondrial exchange: tunneling nanotubes (TNTs), extracellular vesicles (EVs), and freely released mitochondria. TNTs are cytoskeletal bridges — thin ones containing only F-actin, thick ones also incorporating microtubules — through which mitochondria travel directionally or bidirectionally depending on cellular stress context. Under hypoxia, fibroblast-to-cardiomyocyte TNT-mediated transfer becomes unidirectional, suggesting a stress-adaptive support mechanism. EV-mediated transfer involves either intact mitochondria or smaller mitochondria-derived vesicles (MDVs, ~60–150 nm), which bud selectively from mitochondrial membranes in a PINK1/Parkin-dependent or -independent fashion, preceding and complementing canonical mitophagy.

Two functional axes organize the biology: 'Rescue by Replenish' describes healthy mitochondria donated to stressed recipient cells, restoring membrane potential, ATP production, and suppressing apoptosis. Mesenchymal stem cells (MSCs) are a dominant donor cell type, shown to transfer mitochondria to cardiomyocytes, endothelial cells, and immune cells across multiple preclinical models including ischemia-reperfusion injury, anthracycline cardiotoxicity, and heart failure. 'Relief by Release' describes the active extrusion of damaged mitochondria by stressed donor cells — a cytoprotective detoxification pathway that limits inflammasome activation and preserves cellular homeostasis, functionally complementary to intracellular mitophagy.

Four translational strategies emerge: (1) cell-based therapies using MSCs or other donor cells to deliver healthy mitochondria or scavenge damaged ones; (2) mitochondria-containing EV preparations as cell-free therapeutics; (3) isolated, purified free mitochondria for direct administration; and (4) pharmacologic, nutritional, and lifestyle interventions — including exercise, NAD+ precursors, and mitophagy-enhancing compounds — that amplify endogenous mitochondrial turnover and intercellular exchange.

Despite compelling preclinical evidence, substantial barriers remain. Inflammatory and oncogenic risks accompany exogenous mitochondrial transfer. Mitonuclear incompatibility between donor and recipient genomes may impair oxidative phosphorylation complex assembly. The intracellular fate, functional durability, and immunogenicity of transferred mitochondria are poorly characterized. Critically, no standardized manufacturing protocols, potency assays, or long-term storage solutions exist, limiting scalability and regulatory approval pathways. The authors argue that integration of mechanistic biology, bioengineering, and regulatory science is essential to safely advance these therapies.